Treatment of lung adenocarcinoma with chemotherapy helps mitigate chronic myeloid leukaemia progression: A case report

Nagasue,Kazunori; Kida,Ryotaro; Shigaki,Ryota; Nitanai,Kiichi; Yagita,Akari; Yanada,Hiraku; Umekage,Yasuhiro; Mori,Chie; Minami,Yoshinori; Funayama,Takuya; Yamamoto,Masayo; Tanino,Mishie; Yoshida,Ryohei; Sasaki,Takaaki

doi:10.3892/ol.2024.14777

January-2025 Volume 29 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

January-2025 Volume 29 Issue 1

Full Size Image

Case Report Open Access

Treatment of lung adenocarcinoma with chemotherapy helps mitigate chronic myeloid leukaemia progression: A case report

Authors:
- Kazunori Nagasue
- Ryotaro Kida
- Ryota Shigaki
- Kiichi Nitanai
- Akari Yagita
- Hiraku Yanada
- Yasuhiro Umekage
- Chie Mori
- Yoshinori Minami
- Takuya Funayama
- Masayo Yamamoto
- Mishie Tanino
- Ryohei Yoshida
- Takaaki Sasaki
View Affiliations / Copyright

Affiliations: Department of Internal Medicine, Division of Respiratory Medicine and Neurology, Asahikawa Medical University, Asahikawa, Hokkaido 078‑8510, Japan, Department of Internal Medicine, Division of Hematology, Asahikawa Medical University, Asahikawa, Hokkaido 078‑8510, Japan, Department of Diagnostic Pathology, Asahikawa Medical University Hospital, Asahikawa, Hokkaido 078‑8510, Japan

Copyright: © Nagasue et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Article Number: 31
|
Published online on: October 25, 2024

https://doi.org/10.3892/ol.2024.14777
Expand metrics +

Abstract

Treatment outcomes for inoperable advanced non‑small cell lung cancer have improved in recent years. However, information on coexisting haematological tumours is lacking. The present patient was a 65‑year‑old woman with stage IVA lung adenocarcinoma. The patient was administered a combination of platinum therapy and immune checkpoint inhibitors. The patient was subsequently diagnosed with chronic myeloid leukaemia (CML) following leukocytosis. Carboplatin and pemetrexed combination therapy resulted in shrinkage of lung cancer. Improvements in peripheral blood leukocyte counts and bone marrow findings were observed. These results suggested that the treatment of lung cancer may control the course of CML.

View Figures

View References

1	Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al: Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥ 50. J Clin Oncol. 39:2339–2349. 2021. View Article : Google Scholar : PubMed/NCBI
2	Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Gao S, Chen KN, Dooms C, Majem M, Eigendorff E, et al: Perioperative pembrolizumab for early-stage non-small-cell lung cancer. N Engl J Med. 389:491–503. 2023. View Article : Google Scholar : PubMed/NCBI
3	Tabuchi T, Ito Y, Ioka A, Miyashiro I and Tsukuma H: Incidence of metachronous second primary cancers in Osaka, Japan: Update of analyses using population-based cancer registry data. Cancer Sci. 103:1111–1120. 2012. View Article : Google Scholar : PubMed/NCBI
4	Travis LB: The epidemiology of second primary cancers. Cancer Epidemiol Biomarkers Prev. 15:2020–2026. 2006. View Article : Google Scholar : PubMed/NCBI
5	Montefusco E, Petti MC, Alimena G, Latagliata R, Celesti F, Capria S, Amadori S, Avvisati G and Mandelli F: Etoposide, intermediate-dose cytarabine and carboplatin (VAC): A combination therapy for the blastic phase of chronic myelogenous leukemia. Ann Oncol. 8:175–179. 1997. View Article : Google Scholar : PubMed/NCBI
6	Kantarjian H, O'Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J, Rios MB, Ravandi F, Faderl S, Kadia T, et al: Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: A single-institution historical experience. Blood. 119:1981–1987. 2012. View Article : Google Scholar : PubMed/NCBI
7	Wylie AA, Schoepfer J, Jahnke W, Cowan-Jacob SW, Loo A, Furet P, Marzinzik AL, Pelle X, Donovan J, Zhu W, et al: The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature. 543:733–737. 2017. View Article : Google Scholar : PubMed/NCBI
8	Koo SM, Kim KU, Kim YK and Uh ST: Therapy-related myeloid leukemia during erlotinib treatment in a non-small cell lung cancer patient: A case report. World J Clin Cases. 9:7205–7211. 2021. View Article : Google Scholar : PubMed/NCBI
9	McNerney ME, Godley LA and Le Beau MM: Therapy-related myeloid neoplasms: When genetics and environment collide. Nat Rev Cancer. 17:513–527. 2017. View Article : Google Scholar : PubMed/NCBI
10	Kim HB, Park SG, Hong R, Kang SH and Na YS: Acute myelomonocytic leukemia during pembrolizumab treatment for non-small cell lung cancer: A case report. World J Clin Cases. 8:2833–2840. 2020. View Article : Google Scholar : PubMed/NCBI
11	Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M and Vardiman JW: The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 127:2391–2405. 2016. View Article : Google Scholar : PubMed/NCBI
12	Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G, Guilhot F, Porkka K, Ossenkoppele G, Lindoerfer D, et al: Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: The EUTOS score. Blood. 118:686–692. 2011. View Article : Google Scholar : PubMed/NCBI
13	Ren M, Hong M, Liu G, Wang H, Patel V, Biddinger P, Silva J, Cowell J and Hao Z: Novel FGFR inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing FGFR1. Oncol Rep. 29:2181–2190. 2013. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Treatment of lung adenocarcinoma with chemotherapy helps mitigate chronic myeloid leukaemia progression: A case report

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Related Articles